mTOR-inhibitor-based immunosuppression following liver transplantation for Hereditary Hemorrhagic Telangiectasia.
We have read with interest the article by Dumortier et al. reporting that patients with hereditary hemorrhagic telangiectasia (HHT) have a high radiological recurrence rate after liver transplantation (LT) with an estimated cumulative risk of 47.9% at 15 years, although clinical consequences in terms of symptomatic liver disease are unknown. Immunosuppressant regimen used in these patients was based in calcineurin inhibitors (tacrolimus and ciclosporin) with addition to mycophenolate mophetil when necessary. The authors suggest the possible role of antiangiogenic medications such bevacizumab as adjuvant therapy to LT when radiological recurrent disease appears. This article is protected by copyright. All rights reserved.